ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia

Authors: Daniel Gaudet, Daniel A. Gipe, Robert Pordy, Zahid Ahmad, Marina Cuchel, Prediman K. Shah, Kuang-Yuh Chyu, William J. Sasiela, Kuo‐Chen Chan, Diane Brisson, Étienne Khoury, Poulabi Banerjee, Viktoria Gusarova, Jesper Gromada, Neil Stahl, George D. Yancopoulos, G. Kees Hovingh - New England Journal of Medicine, NEJM 2017 cited by 329

Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.